NNVC revenueQ4 2026$0
NNVC revenue was $0 in fiscal Q4 2026 (ended Jun 30, 2026), compared with $0 a year earlier. For the full fiscal 2026 it was $0, compared with $0 in fiscal 2025.
NanoViricides Inc. (NNVC) financials
For fiscal 2026 (ended Jun 30, 2026), NanoViricides Inc. reported $0 of revenue and -$8.22M of net income.
- Revenue, FY2026
- $0
- Net income, FY2026
- -$8.22M
- Free cash flow, FY2026
- -$7.78M
- EPS, diluted, FY2026
- -$0.41
- Cash
- $2.79M
- Market cap
- $33.7M
FY2023FY2026
FY2017FY2026
FY2017FY2026
NNVC revenue and earnings growth
NNVC net incomeQ4 2026-$2.22M
NNVC net income was -$2.22M in fiscal Q4 2026 (ended Jun 30, 2026), compared with -$2.10M a year earlier. For the full fiscal 2026 it was -$8.22M, compared with -$9.47M in fiscal 2025.
NNVC EPSFY2026-$0.41
NNVC diluted EPS was -$0.41 for fiscal 2026 (ended Jun 30, 2026), compared with -$0.63 in fiscal 2025.
NNVC free cash flowQ4 2026-$2.12M
NNVC free cash flow was -$2.12M in fiscal Q4 2026 (ended Jun 30, 2026), compared with -$1.71M a year earlier. For the full fiscal 2026 it was -$7.78M, compared with -$8.54M in fiscal 2025.
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | - | - | - | - | - | - |
| Research and development | $4.71M | $5.55M | $5.44M | $6.39M | $5.78M | $6.11M | $4.70M | $5.92M | $5.91M | $6.57M |
| Selling, general and admin | $3.60M | $4.04M | $3.08M | $2.55M | $2.33M | $2.63M | $3.30M | $2.74M | $3.41M | $3.03M |
| Operating income | -$8.31M | -$9.59M | -$8.52M | -$8.94M | -$8.11M | -$8.74M | -$8.00M | -$8.66M | -$9.33M | -$9.60M |
| Interest expense | - | $149 | $49.8K | $938 | $5.1K | $85.4K | $93.7K | $0 | $185.3K | $780.8K |
| Pre-tax income | -$8.22M | - | - | - | -$8.11M | -$8.82M | -$13.45M | -$8.42M | -$8.56M | -$10.30M |
| Income tax | - | - | - | - | - | - | $0 | $0 | $0 | $0 |
| Net income | -$8.22M | -$9.47M | -$8.29M | -$8.59M | -$8.11M | -$8.82M | -$13.45M | -$8.42M | -$8.56M | -$10.30M |
| EPS, basic | -$0.41 | -$0.63 | -$0.70 | -$0.74 | -$0.70 | -$0.81 | -$2.39 | -$2.35 | -$2.64 | -$3.40 |
| EPS, diluted | -$0.41 | -$0.63 | -$0.70 | -$0.74 | -$0.70 | -$0.81 | -$2.39 | -$2.35 | -$2.64 | -$3.40 |
| Diluted shares | 20.2M | 15.1M | 11.9M | 11.6M | 11.5M | 10.9M | 5.6M | 3.6M | 3.2M | 3.0M |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.79M | $1.56M | $4.80M | $8.15M | $14.07M | $20.52M | $13.71M | $2.56M | $7.08M | $15.10M |
| Current assets | $3.16M | $1.67M | $4.97M | $8.45M | $14.42M | $20.82M | $13.99M | $2.83M | $7.32M | $15.29M |
| Total assets | $9.87M | $8.82M | $12.82M | $16.90M | $23.49M | $30.26M | $23.91M | $13.45M | $18.55M | $27.00M |
| Current liabilities | $1.19M | $1.31M | $1.36M | $534.3K | $412.8K | $351.1K | $2.16M | $2.85M | $881.9K | $4.67M |
| Total liabilities | $1.20M | $1.30M | $1.36M | $2.03M | $412.8K | - | - | - | $881.9K | $6.68M |
| Shareholders' equity | $8.68M | $7.52M | $11.46M | $14.87M | $23.08M | $29.91M | $21.76M | $10.60M | $17.66M | $20.32M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.70M | -$8.48M | -$6.32M | -$5.67M | -$5.89M | -$8.21M | -$6.67M | -$6.80M | -$7.78M | -$7.90M |
| Capital expenditures | $84.3K | $57.0K | $156.6K | $151.7K | $324.3K | $238.8K | $8.6K | $73.8K | $241.8K | $165.0K |
| Free cash flow | -$7.78M | -$8.54M | -$6.47M | -$5.82M | -$6.22M | -$8.45M | -$6.67M | -$6.88M | -$8.02M | -$8.06M |
| Investing cash flow | -$84.3K | -$57.0K | -$156.6K | -$151.7K | -$324.3K | - | - | - | - | -$165.0K |
| Financing cash flow | $9.02M | $5.30M | $3.12M | -$94.8K | -$234.7K | $15.26M | $17.83M | $2.35M | $0 | -$1.00M |
| Stock-based compensation | - | - | - | - | - | - | - | $35.8K | $156.2K | - |
Key ratios
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -94.7% | -125.9% | -72.3% | -57.8% | -35.1% | -29.5% | -61.8% | -79.5% | -48.5% | -50.7% |
| Return on assets | -83.2% | -107.3% | -64.7% | -50.8% | -34.5% | -29.2% | -56.2% | -62.6% | -46.2% | -38.2% |
| Current ratio | 2.66 | 1.28 | 3.66 | 15.81 | 34.92 | 59.30 | 6.49 | 0.99 | 8.30 | 3.28 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $1.31M | $1.29M | $1.12M | $993.1K | $1.18M | $1.28M | $1.16M | $1.93M | $1.18M | $1.21M | $1.57M | $1.47M |
| Selling, general and admin | $936.3K | $744.3K | $1.11M | $803.6K | $938.2K | $966.9K | $902.7K | $1.23M | $1.21M | $693.7K | $610.9K | $564.9K |
| Operating income | -$2.25M | -$2.03M | -$2.23M | -$1.80M | -$2.12M | -$2.25M | -$2.06M | -$3.17M | -$2.39M | -$1.91M | -$2.18M | -$2.03M |
| Interest expense | - | - | - | - | $0 | $0 | $149 | $0 | $0 | $0 | $13.3K | $36.5K |
| Pre-tax income | - | - | - | - | - | - | - | - | - | - | - | -$1.97M |
| Net income | -$2.22M | -$1.99M | -$2.22M | -$1.79M | -$2.10M | -$2.22M | -$2.03M | -$3.13M | -$2.36M | -$1.85M | -$2.11M | -$1.97M |
| EPS, basic | - | -$0.09 | -$0.11 | -$0.10 | -$0.12 | -$0.14 | -$0.14 | -$0.23 | -$0.19 | -$0.16 | -$0.18 | -$0.17 |
| EPS, diluted | - | -$0.09 | -$0.11 | -$0.10 | -$0.12 | -$0.14 | -$0.14 | -$0.23 | -$0.19 | -$0.16 | -$0.18 | -$0.17 |
| Diluted shares | - | 21.6M | 19.9M | 17.1M | - | 16.0M | 14.6M | 13.7M | - | 11.8M | 11.7M | 11.7M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.79M | $3.21M | $5.15M | $1.13M | $1.56M | $2.54M | $3.96M | $3.87M | $4.80M | $3.26M | $5.25M | $6.97M |
| Current assets | $3.16M | $3.38M | $5.30M | $1.25M | $1.67M | $2.73M | $4.07M | $4.04M | $4.97M | $3.52M | $5.32M | $7.14M |
| Total assets | $9.87M | $10.22M | $12.27M | $8.36M | $8.82M | $10.03M | $11.57M | $11.74M | $12.82M | $11.46M | $13.40M | $15.42M |
| Current liabilities | $1.19M | $1.07M | $1.20M | $1.18M | $1.31M | $1.20M | $1.18M | $1.63M | $1.36M | $813.3K | $951.1K | $948.3K |
| Total liabilities | $1.20M | $1.10M | $1.20M | $1.20M | $1.30M | - | $1.20M | $1.63M | $1.36M | $813.3K | $951.1K | $2.45M |
| Shareholders' equity | $8.68M | $9.15M | $11.07M | $7.17M | $7.52M | $8.83M | $10.39M | $10.11M | $11.46M | $10.65M | $12.45M | $12.97M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.12M | -$1.93M | -$2.05M | -$1.59M | -$1.70M | -$1.99M | -$2.19M | -$2.59M | -$1.48M | -$1.94M | -$1.72M | -$1.17M |
| Capital expenditures | $1 | $0 | -$1 | $84.3K | $10.2K | $0 | $0 | $46.8K | $98.2K | $44.6K | $5.5K | $8.3K |
| Free cash flow | -$2.12M | -$1.93M | -$2.05M | -$1.68M | -$1.71M | -$1.99M | -$2.19M | -$2.64M | -$1.58M | -$1.99M | -$1.72M | -$1.18M |
| Investing cash flow | -$1 | $0 | $1 | -$84.3K | -$10.2K | $0 | $0 | -$46.8K | -$98.2K | -$44.6K | -$5.5K | -$8.3K |
| Financing cash flow | $1.70M | -$6.7K | $6.07M | $1.25M | $728.1K | $575.5K | $2.28M | $1.71M | $3.12M | $0 | $0 | $0 |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 2.66 | 3.17 | 4.43 | 1.06 | 1.28 | 2.27 | 3.44 | 2.48 | 3.66 | 4.32 | 5.59 | 7.53 |
Source: XBRL data NanoViricides Inc. files with the SEC, latest filing dated Sep 28, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Nov 15, 2019.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
NNVC peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NNVC | $0 | - | -$8.22M | - | $33.7M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
NNVC FAQ
7 questionsWhat is NNVC revenue?
NanoViricides Inc. (NNVC) reported $0 of revenue for fiscal 2026 (ended Jun 30, 2026).Is NNVC profitable?
No. NanoViricides Inc. reported a net loss of $8.22M for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does NNVC have?
NanoViricides Inc. reported $2.79M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is NNVC free cash flow?
NanoViricides Inc. generated -$7.78M of free cash flow for fiscal 2026 (ended Jun 30, 2026), which is operating cash flow of -$7.70M less capital expenditures.What is NNVC earnings per share?
Diluted earnings per share were -$0.41 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did NNVC last report financial results?
The latest statements here come from NanoViricides Inc.'s 10-K filed on Sep 28, 2026, covering the period ended Jun 30, 2026.Where does this NNVC financial data come from?
Quantisnow builds these statements from the structured XBRL data NanoViricides Inc. files with the SEC. It is provided for information only and is not investment advice.